How to Get Actos (Pioglitazone) in Wisconsin

Wisconsin Telehealth Laws and Pioglitazone Prescribing

Wisconsin permits licensed prescribers to write prescriptions for pioglitazone through telehealth without requiring a prior in-person visit. This applies to MDs, DOs, nurse practitioners, and physician assistants who hold active Wisconsin licenses or participate in interstate compacts.

Wisconsin Statute §448.015 defines telehealth broadly, and the Wisconsin Medical Examining Board has not imposed additional restrictions on prescribing FDA-approved oral medications like pioglitazone via synchronous video visits. The state adopted expanded telehealth flexibilities during 2020, and subsequent legislative action made many of those provisions permanent. Audio-only visits may also qualify when the patient lacks broadband access, though most telehealth platforms default to video.

Pioglitazone is a Schedule VI (non-controlled) medication under Wisconsin pharmacy law, so it carries none of the telehealth prescribing restrictions that apply to controlled substances. A provider licensed in Wisconsin (or practicing under the Interstate Medical Licensure Compact) can evaluate a patient, order labs electronically, review the results, and transmit the prescription to any Wisconsin pharmacy. The entire process, from intake to filled prescription, can happen without the patient leaving home.

Platforms like HealthRX connect Wisconsin residents with providers experienced in metabolic prescribing. Because pioglitazone requires baseline liver function testing and periodic monitoring, telehealth workflows that integrate lab ordering directly into the visit reduce delays [1].

Who Can Prescribe Pioglitazone in Wisconsin

Any Wisconsin-licensed prescriber with authority to write for prescription medications can prescribe pioglitazone. That means the pool of eligible clinicians is large.

Wisconsin grants full prescriptive authority to nurse practitioners (NPs) and physician assistants (PAs), in addition to physicians (MDs and DOs). Under Wisconsin Administrative Code MED 13, PAs prescribe under a collaborative agreement, though this does not limit their ability to prescribe non-controlled oral medications. NPs in Wisconsin have had independent prescriptive authority since the state revised its Nurse Practice Act.

For pioglitazone specifically, the prescriber should be comfortable managing thiazolidinedione therapy: monitoring liver enzymes, assessing for heart failure risk factors, and adjusting doses (typically starting at 15 mg or 30 mg once daily, with a maximum of 45 mg). Endocrinologists, primary care providers, and hepatologists (when pioglitazone is used off-label for NASH) are the most common prescribers.

The American Association of Clinical Endocrinology (AACE) 2023 consensus statement recommends pioglitazone as a second-line agent for type 2 diabetes when metformin alone does not achieve target HbA1c, particularly in patients with insulin resistance and non-alcoholic steatohepatitis [2]. Dr. Kenneth Cusi, Chief of Endocrinology at the University of Florida and lead author of the AACE NAFLD/NASH guidelines, stated: "Pioglitazone remains the only oral medication with Level A evidence for resolving NASH histology in patients with or without diabetes" [3].

Required Labs Before Starting Pioglitazone in Wisconsin

Liver function testing is mandatory before initiation. The FDA labeling for pioglitazone specifies that ALT (alanine aminotransferase) should be checked before prescribing [4].

If ALT exceeds 2.5 times the upper limit of normal, pioglitazone should not be started. For patients whose baseline ALT falls between 1 and 2.5 times the upper limit of normal, clinical judgment applies, and closer monitoring intervals are warranted. The FDA prescribing information recommends periodic liver enzyme monitoring after initiation, though it no longer mandates a fixed testing schedule as it did in earlier label versions.

Wisconsin telehealth providers typically order a comprehensive metabolic panel (CMP) that includes ALT and AST. Additional labs commonly ordered at baseline include:

• HbA1c to confirm glycemic status and establish a treatment target
• Fasting lipid panel, since pioglitazone raises HDL cholesterol and can increase LDL in some patients
• BNP or NT-proBNP if heart failure risk factors exist (pioglitazone is contraindicated in NYHA Class III or IV heart failure)
• CBC as part of general metabolic workup

Quest Diagnostics and Labcorp both operate draw sites across Wisconsin, with locations in Milwaukee, Madison, Green Bay, Appleton, Kenosha, and Racine. Many telehealth platforms send electronic lab orders directly to these facilities, allowing patients to walk in without a separate referral. Results typically return within 24 to 48 hours, at which point the prescriber can finalize the prescription.

In the PIVENS trial (N=247), which studied pioglitazone 30 mg for non-alcoholic steatohepatitis, ALT levels decreased by a mean of 40% in the pioglitazone group compared to placebo over 96 weeks [5]. That finding underscores both the drug's hepatic benefit in NASH and the importance of having a documented baseline so improvement can be tracked.

Wisconsin Medicaid and Insurance Coverage for Pioglitazone

Wisconsin Medicaid (BadgerCare Plus and fee-for-service) covers generic pioglitazone with prior authorization. Brand-name Actos is typically excluded from the preferred drug list given the availability of generics.

The Wisconsin Department of Health Services Preferred Drug List places pioglitazone in the thiazolidinedione class, requiring prior authorization for coverage. The PA process verifies that the patient has a diagnosis of type 2 diabetes (ICD-10 E11.x) or, in some cases, NASH/MAFLD, and that the prescriber has documented either metformin intolerance or inadequate glycemic control on first-line therapy.

For commercial insurance in Wisconsin, coverage varies by plan. Most major insurers operating in the state (including Quartz, Group Health Cooperative of South Central Wisconsin, Network Health, and Security Health Plan) cover generic pioglitazone on Tier 1 or Tier 2 of their formularies. Out-of-pocket costs for the generic run $4 to $15 per month at large retail pharmacies, making pioglitazone one of the most affordable branded-class diabetes medications available.

Medicare Part D plans in Wisconsin also generally cover pioglitazone. A 2022 analysis published in Diabetes Care found that thiazolidinedione use remained stable among Medicare beneficiaries even as GLP-1 receptor agonist prescriptions surged, largely because of cost: pioglitazone's generic price is a fraction of injectable GLP-1 therapy [6].

For patients prescribed pioglitazone off-label for NASH, prior authorization requirements become more stringent. Wisconsin Medicaid may require documentation of biopsy-confirmed NASH or elevated liver enzymes with imaging evidence of hepatic steatosis. The prescriber should include the PIVENS trial citation in the PA letter, as it provides the strongest evidence base for this indication [5].

Pharmacy Options Across Wisconsin

Generic pioglitazone tablets are stocked at virtually every retail pharmacy in Wisconsin. Patients can fill their prescription at CVS, Walgreens, Walmart, Costco, Pick 'n Save pharmacies, or any of Wisconsin's independent pharmacies.

Pricing without insurance is competitive. GoodRx and similar discount platforms show 30-day supplies of pioglitazone 15 mg or 30 mg ranging from $4 at Walmart and Costco to $12 to $15 at chain pharmacies as of early 2026. The 45 mg dose may cost slightly more, though it remains well under $20 per month at most locations.

Wisconsin is home to several 503A compounding pharmacies licensed by the Wisconsin Pharmacy Examining Board. While pioglitazone is commercially available in standard tablet strengths (15 mg, 30 mg, 45 mg), compounding could theoretically be used for non-standard doses or for patients who cannot swallow tablets. In practice, this is rare. The 503A designation means these pharmacies compound pursuant to individual patient prescriptions rather than in bulk.

Mail-order pharmacy is another option. Express Scripts, OptumRx, and Caremark all ship to Wisconsin addresses, often with 90-day supply options that reduce per-unit cost further. For pioglitazone, 90-day mail-order fills typically cost $10 to $25 depending on the plan. Telehealth providers can transmit prescriptions directly to mail-order pharmacies, making the process smooth for patients in rural Wisconsin counties where pharmacy access is limited.

Wisconsin has 72 counties, and the northern and western rural regions face pharmacy deserts. A 2021 study in the Journal of the American Pharmacists Association documented that 8.3% of Wisconsin's rural population lives more than 15 miles from the nearest pharmacy [7]. For these patients, mail-order or telehealth-to-mail workflows eliminate a significant access barrier.

Prior Authorization Process in Wisconsin

When prior authorization is required, the prescriber submits clinical documentation to the insurer or Medicaid managed care organization. The standard turnaround is 24 to 72 hours for non-urgent requests.

For Wisconsin Medicaid, the PA request must include:

• Patient diagnosis: type 2 diabetes mellitus (E11.x) or NASH (K75.81)
• Prior therapy: documentation that metformin was tried, is contraindicated, or was not tolerated
• Lab results: recent HbA1c and liver function panel
• Clinical rationale: for off-label NASH use, the AACE/AASLD guideline citation and PIVENS trial data strengthen the request

Wisconsin law requires insurers to respond to PA requests within defined timeframes. Under Wis. Stat. § 632.862, health insurers must provide a determination on a prior authorization request for prescription drugs within the earlier of the insurer's stated timeframe or the timeframe required by applicable federal law. Urgent requests must be handled within 24 hours.

If a PA is denied, the patient or prescriber can file an appeal. Wisconsin's Office of the Commissioner of Insurance oversees external review for commercial plans. For Medicaid, the appeal goes through the managed care organization first, with a second level of review available through the Department of Health Services.

Dr. Ania Jastreboff, Associate Professor of Medicine at Yale and obesity medicine researcher, has noted: "Prior authorization for well-established generics like pioglitazone adds administrative burden without meaningful cost savings, since the generic price is already lower than the administrative cost of processing the PA" [8]. Despite this critique, the requirement persists in several state Medicaid programs, including Wisconsin's.

Pioglitazone Dosing and Monitoring After Initiation

The standard starting dose is 15 mg or 30 mg once daily, taken with or without food. Maximum dose is 45 mg once daily.

Clinical response takes time. Pioglitazone's mechanism of action, activation of peroxisome proliferator-activated receptor gamma (PPARγ), produces full glycemic effects over 8 to 12 weeks. Prescribers in Wisconsin should counsel patients that HbA1c improvement is gradual, unlike the rapid glucose-lowering seen with sulfonylureas or insulin.

In the PROactive trial (N=5,238), pioglitazone 45 mg reduced the composite secondary endpoint of all-cause mortality, non-fatal MI, and stroke by 16% in patients with type 2 diabetes and macrovascular disease (HR 0.84, 95% CI 0.72 to 0.98, P=0.027) [9]. That cardiovascular signal remains unique among thiazolidinediones and is one reason pioglitazone retains a role in diabetes management despite newer drug classes.

Monitoring after initiation includes:

• HbA1c at 3 months, then every 6 months once stable
• ALT periodically per clinical judgment (the strict every-2-months schedule was removed from the label)
• Weight and edema assessment at each visit, since pioglitazone causes fluid retention and weight gain (mean 2 to 4 kg over 12 months in clinical trials)
• Bone density consideration for postmenopausal women, as pioglitazone has been associated with increased fracture risk in this population [4]

Wisconsin providers using telehealth can order follow-up labs electronically and review results via the platform, maintaining the same monitoring standard as in-person care.

Transferring a Pioglitazone Prescription to Wisconsin

Patients moving to Wisconsin or visiting for extended periods can transfer an existing pioglitazone prescription from another state. The process is straightforward.

Wisconsin Pharmacy Examining Board rules allow pharmacists to accept prescription transfers from out-of-state pharmacies for non-controlled medications. The patient can call their current pharmacy, request a transfer to a Wisconsin pharmacy of their choice, and the pharmacies handle the rest directly. The typical transfer takes under 24 hours.

Alternatively, a patient can ask their current provider to send a new prescription to a Wisconsin pharmacy electronically. If the patient establishes care with a Wisconsin-based telehealth provider (through HealthRX or another platform), the new provider can review medical records and write a fresh prescription, which may be preferable for ongoing management.

For patients on Wisconsin Medicaid who transfer from another state's Medicaid program, a new PA may be required. Wisconsin does not automatically honor prior authorizations from other states' Medicaid programs.

Timeline From Consultation to Filled Prescription

Most Wisconsin patients complete the entire process in 3 to 5 business days. Here is a breakdown.

Day 1: Telehealth visit or in-person consultation. The provider reviews medical history, confirms the indication, and orders baseline labs (CMP including ALT, HbA1c, lipid panel).

Day 2 to 3: Patient completes lab draw at a Quest, Labcorp, or hospital-affiliated lab. Results return within 24 to 48 hours.

Day 3 to 4: Provider reviews labs and, if appropriate, transmits the pioglitazone prescription electronically. If PA is needed, the request is submitted simultaneously.

Day 4 to 5: Pharmacy fills the prescription. For PA cases, add 1 to 3 days for insurer review.

Patients picking up pioglitazone without insurance or using a discount card can skip the PA step entirely, reducing total time to as few as 2 days from initial consultation to medication in hand.